GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.
Original Article: GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy